Glaukos falls 6.3% after three-year Epioxa results and retinal licensing deal

What happened

Glaukos (GKOS) fell 6.3% on October 8, 2026, after it reported three-year durability data for Epioxa and disclosed an exclusive license for a retinal biologic. The decline outpaced both the market and the healthcare sector on the day. The stock opened 0.9% below the previous close and finished with trading volume at 3.2 times its 20-day average, suggesting heavy investor activity after the announcements. Reuters and Business Wire reported the clinical durability results and the licensing agreement.

How big was the move

The stock fell 6.3%, a move described as 2.5 times a typical daily move for this stock. By comparison, the S&P 500 fell 0.5% on the day while the healthcare sector median fell 0.5%, leaving the stock 5.8 percentage points worse than the sector median. Over the last five sessions the stock fell 1.2%. Market sensitivity is a beta of 0.96, meaning the stock tends to move about as much as the market; this session was far more volatile, consistent with a large company-specific reaction to news. In the past five years the stock had 18 sessions with a decline of at least 6.3%; twenty trading days later the median result was a gain of 1.1% and 10 of 18 were higher.

The technical picture

The stock traded 0.8% below its 20-day moving average and 6.7% below its 50-day moving average, while remaining 18.6% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 90 consecutive trading days above the 200-day average. Its Relative Strength Index (14 days) is 45, in a neutral range between 30 and 70. The shares are 15.8% below the 52-week high. Over one month the stock fell 10.3%, while over three months it rose 5.6% and over one year it rose 91.8%, which is 76.2 percentage points ahead of the S&P 500. Volatility is 40% annualized over 60 days, lower than 63% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, Glaukos reported revenue of $612.8 million, which grew 41.5% from a year earlier and followed revenue growth of 36.3% one quarter earlier. Diluted earnings per share for that period were $-3.25. Gross margin was 79.1% compared with 76.3% a year earlier, while operating margin was 13.1% compared with 22.3% a year earlier. Free-cash-flow margin was 2.0% and return on invested capital was 9.6%. The company reported net cash of $11.6 million on the balance sheet, and share count over one year increased by 2.1%. On valuation, free-cash-flow yield is 0.1%.

Those figures point to a company with strong top-line growth and high gross margins but modest free-cash-flow generation. Revenue growth of 41.5% and a gross margin of 79.1% underline the commercial strength of Glaukos’s device and therapy franchise. Operating margin has compressed from a year earlier and free-cash-flow yield is effectively negligible at 0.1%, leaving limited current cash returns for investors despite rapid growth.

Earnings and analyst expectations

Glaukos last reported on July 29, 2026, with earnings per share of $-0.14 against $-0.21 expected, a result 33.5% above estimates. That marked two consecutive quarters beating estimates, and the average surprise over the last four reports was 21.7% above estimates. The typical two-day reaction after recent reports has been a fall of 0.1%. The company has its next report scheduled for November 4, 2026.

Analysts’ consensus price target is $192.89, which is 19.6% above the closing price on October 8, 2026, based on 25 analysts covering the stock; 72% of those ratings are Buy and the consensus rating is Buy. The sell-side view, combined with two consecutive beats, indicates ongoing analyst confidence. The market’s reaction to the clinical and licensing news shows investors are weighing near-term uncertainty around pipeline development and commercial cadence.

What to watch

• November 4, 2026: Glaukos next reports quarterly results.
• The long-term follow-up data and safety signals from the Phase 3 extension study GLK-202-03, which Reuters and Business Wire reported as showing durable improvements three years after a single Epioxa treatment.
• Integration and development milestones tied to the exclusive license agreement with RevOpsis Therapeutics for RO-104, as reported by Business Wire and Benzinga.
• Trading volume relative to the 20-day average and any shifts in short interest after the announcements.
• Changes in analyst estimates or the consensus price target following the clinical and licensing news.